Scott Michael Palmer, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Vice-Chair for Research in the Department of Medicine
Professor in Immunology
Professor in Population Health Sciences
Core Faculty in Innovation & Entrepreneurship
Campus mail 2085 Msrb2 2 Genome Ct, Durham, NC 27710
Phone (919) 684-0245
Email address

Dr. Palmer leads a successful program of clinical, basic and translational research in transplantation and advanced lung diseases. He currently directs the pulmonary research program at the Duke Clinical Research Institute (DCRI) and serves as Vice Chair for Research in the Department of Medicine.

Dr. Palmer has over 150 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is also Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers.

His scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.

Current basic projects in the lab are studying the role of the matrix in the activation of innate immunity in pulmonary transplant rejection, and epithelial injury and repair in the development of toxin induced bronchiolitis obliterans. Translational and human projects are studying predictors of lung transplant survival in the UNOS database, immune monitoring to predict CMV infection and acute rejection after lung transplantation, and the use of novel inhaled antibiotics in lung transplantation. The lab is also using cutting edge whole exome genetic sequencing to identify genetic predictors of transplant rejection.

Dr. Palmer also leads trials coordinated through the DCRI that study the natural history and investigate new treatments for idiopathic pulmonary fibrosis (IPF), chronic lung transplant rejection, and posttransplant cytomegalovirus infection.

Education and Training

  • Fellow, Pulmonary Medicine, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2000
  • M.D., Duke University, 1993


Klement, W., J. Tikkanen, S. Juvet, J. L. Todd, S. S. Weigt, L. D. Snyder, S. Azad, et al. “Automating the Diagnosis of Potential CLAD and Its Subtypes in Lung Transplant Recipients.” In Journal of Heart and Lung Transplantation, 36:S309–S309. ELSEVIER SCIENCE INC, 2017.


Smith, P. J., J. A. Blumenthal, L. D. Snyder, S. Rivelli, and S. M. Palmer. “Perceived Cognitive Difficulties and Quality of Life following Lung Transplantation.” In Journal of Heart and Lung Transplantation, 36:S96–S96. ELSEVIER SCIENCE INC, 2017.


Zaffiri, L., C. Frankel, E. N. Pavlisko, S. M. Palmer, and L. D. Snyder. “Post-Transplant Lymphoproliferative Disorder After Lung Transplantation: 10-Year Experience at Duke University.” In Journal of Heart and Lung Transplantation, 36:S95–S95. ELSEVIER SCIENCE INC, 2017.


Vacha, Mary, Godefroy Chery, Amanda Hulbert, Jennifer Byrns, Clark Benedetti, Catherine Ashley Finlen Copeland, Alice Gray, Oluwatoyosi Onwuemene, Scott M. Palmer, and Laurie D. Snyder. “Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?” Clin Transplant 31, no. 3 (March 2017).

Full Text

Foster, Matthew W., William M. Gwinn, Francine L. Kelly, David M. Brass, Ashlee M. Valente, M Arthur Moseley, J Will Thompson, Daniel L. Morgan, and Scott M. Palmer. “Proteomic Analysis of Primary Human Airway Epithelial Cells Exposed to the Respiratory Toxicant Diacetyl.” J Proteome Res 16, no. 2 (February 3, 2017): 538–49.

Full Text

Vock, David M., Michael T. Durheim, Wayne M. Tsuang, C Ashley Finlen Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. “Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation.” Ann Am Thorac Soc 14, no. 2 (February 2017): 172–81.

Full Text

Smith, Patrick J., James A. Blumenthal, Laurie D. Snyder, Joseph P. Mathew, Michael T. Durheim, Benson M. Hoffman, Sarah K. Rivelli, and Scott M. Palmer. “Depressive symptoms and early mortality following lung transplantation: A pilot study.” Clin Transplant 31, no. 2 (February 2017).

Full Text

Tong, Yubing, Jayaram K. Udupa, Drew A. Torigian, Dewey Odhner, Caiyun Wu, Gargi Pednekar, Scott Palmer, et al. “Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates.” Plos One 12, no. 1 (January 3, 2017): e0168932.

Full Text

Bates, C. A., C. W. Frankel, A. L. Gray, J. M. Reynolds, S. M. Palmer, and M. L. Neely. “Outcomes In Lung Transplant Recipients With Pulmonary Fibrosis At High Risk Of Death.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.


Todd, J. L., A. J. Mikels-Vigdal, F. L. Kelly, E. N. Pavlisko, I. Mikaelian, T. G. O’Riordan, V. C. Smith, and S. M. Palmer. “Loxl-2 Contributes To The Development Of Obliterative Bronchiolitis (ob) In Humans.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.